These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 30723303)
1. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Martin V; Chiriaco C; Modica C; Acquadro A; Cortese M; Galimi F; Perera T; Gammaitoni L; Aglietta M; Comoglio PM; Vigna E; Sangiolo D Br J Cancer; 2019 Mar; 120(5):527-536. PubMed ID: 30723303 [TBL] [Abstract][Full Text] [Related]
2. Saigi M; Alburquerque-Bejar JJ; Mc Leer-Florin A; Pereira C; Pros E; Romero OA; Baixeras N; Esteve-Codina A; Nadal E; Brambilla E; Sanchez-Cespedes M Clin Cancer Res; 2018 Sep; 24(18):4579-4587. PubMed ID: 29898990 [No Abstract] [Full Text] [Related]
3. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868 [TBL] [Abstract][Full Text] [Related]
4. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Gao Y; Yang J; Cai Y; Fu S; Zhang N; Fu X; Li L Int J Cancer; 2018 Aug; 143(4):931-943. PubMed ID: 29516506 [TBL] [Abstract][Full Text] [Related]
5. BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population. Peng C; Hu Q; Yang F; Zhang H; Li F; Huang C J Immunol; 2019 Feb; 202(3):704-713. PubMed ID: 30567732 [TBL] [Abstract][Full Text] [Related]
6. PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer. Zhang X; Zeng Y; Qu Q; Zhu J; Liu Z; Ning W; Zeng H; Zhang N; Du W; Chen C; Huang JA Int J Clin Oncol; 2017 Dec; 22(6):1026-1033. PubMed ID: 28748356 [TBL] [Abstract][Full Text] [Related]
7. Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cells. Homma S; Hayashi K; Yoshida K; Sagawa Y; Kamata Y; Ito M Int Immunopharmacol; 2018 Jan; 54():39-45. PubMed ID: 29100036 [TBL] [Abstract][Full Text] [Related]
8. Regulation of programmed death ligand 1 expression by interferon-γ and tumour necrosis factor-α in canine tumour cell lines. Owaki R; Deguchi T; Konnai S; Maekawa N; Okagawa T; Hosoya K; Kim S; Sunaga T; Okumura M Vet Comp Oncol; 2023 Jun; 21(2):279-290. PubMed ID: 36802270 [TBL] [Abstract][Full Text] [Related]
9. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling. Wu Q; Zhao Y; Sun Y; Yan X; Wang P Oncol Rep; 2018 Mar; 39(3):1461-1468. PubMed ID: 29328389 [TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers. Cheng CC; Lin HC; Tsai KJ; Chiang YW; Lim KH; Chen CG; Su YW; Peng CL; Ho AS; Huang L; Chang YC; Lin HC; Chang J; Chang YF Mol Carcinog; 2018 Nov; 57(11):1588-1598. PubMed ID: 30035369 [TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression. Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463 [TBL] [Abstract][Full Text] [Related]
12. MET Receptor Tyrosine Kinase Regulates the Expression of Co-Stimulatory and Co-Inhibitory Molecules in Tumor Cells and Contributes to PD-L1-Mediated Suppression of Immune Cell Function. Ahn HK; Kim S; Kwon D; Koh J; Kim YA; Kim K; Chung DH; Jeon YK Int J Mol Sci; 2019 Sep; 20(17):. PubMed ID: 31480591 [TBL] [Abstract][Full Text] [Related]
13. Licochalcone A inhibits interferon-gamma-induced programmed death-ligand 1 in lung cancer cells. Yuan LW; Jiang XM; Xu YL; Huang MY; Chen YC; Yu WB; Su MX; Ye ZH; Chen X; Wang Y; Lu JJ Phytomedicine; 2021 Jan; 80():153394. PubMed ID: 33130472 [TBL] [Abstract][Full Text] [Related]
14. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma. Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270 [TBL] [Abstract][Full Text] [Related]
15. PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. Rotman J; den Otter LAS; Bleeker MCG; Samuels SS; Heeren AM; Roemer MGM; Kenter GG; Zijlmans HJMAA; van Trommel NE; de Gruijl TD; Jordanova ES Front Immunol; 2020; 11():596825. PubMed ID: 33424844 [TBL] [Abstract][Full Text] [Related]
16. A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells. Kim J; Jang H; Lee GJ; Hur Y; Keum J; Jo JK; Yun SE; Park SJ; Park YJ; Choi MJ; Kim KS; Kim J Cells; 2021 Dec; 11(1):. PubMed ID: 35011581 [TBL] [Abstract][Full Text] [Related]
17. PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B. Lu S; Sun Z; Hu W; Yin S; Zhao C; Hu H Cancer Sci; 2021 May; 112(5):1878-1887. PubMed ID: 33583114 [TBL] [Abstract][Full Text] [Related]
18. Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms. Neuwelt AJ; Kimball AK; Johnson AM; Arnold BW; Bullock BL; Kaspar RE; Kleczko EK; Kwak JW; Wu MH; Heasley LE; Doebele RC; Li HY; Nemenoff RA; Clambey ET J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32312906 [TBL] [Abstract][Full Text] [Related]
19. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling. Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543 [TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. Mimura K; Teh JL; Okayama H; Shiraishi K; Kua LF; Koh V; Smoot DT; Ashktorab H; Oike T; Suzuki Y; Fazreen Z; Asuncion BR; Shabbir A; Yong WP; So J; Soong R; Kono K Cancer Sci; 2018 Jan; 109(1):43-53. PubMed ID: 29034543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]